Literature DB >> 16526129

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.

C U Kim1, W Lew, M A Williams, H Liu, L Zhang, S Swaminathan, N Bischofberger, M S Chen, D B Mendel, C Y Tai, W G Laver, R C Stevens.   

Abstract

The design, synthesis, and in vitro evaluation of the novel carbocycles as transition-state-based inhibitors of influenza neuraminidase (NA) are described. The double bond position in the carbocyclic analogues plays an important role in NA inhibition as demonstrated by the antiviral activity of 8 (IC50 = 6.3 microM) vs 9 (IC50 > 200 microM). Structure-activity studies of a series of carbocyclic analogues 6a-i identified the 3-pentyloxy moiety as an apparent optimal group at the C3 position with an IC50 value of 1 nM for NA inhibition. The X-ray crystallographic structure of 6h bound to NA revealed the presence of a large hydrophobic pocket in the region corresponding to the glycerol subsite of sialic acid. The high antiviral potency observed for 6h appears to be attributed to a highly favorable hydrophobic interaction in this pocket. The practical synthesis of 6 starting from (-)-quinic acid is also described.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 16526129     DOI: 10.1021/ja963036t

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  193 in total

1.  Analysis of inhibitor binding in influenza virus neuraminidase.

Authors:  B J Smith; P M Colman; M Von Itzstein; B Danylec; J N Varghese
Journal:  Protein Sci       Date:  2001-04       Impact factor: 6.725

Review 2.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

3.  Development of an Antiviral Screening Protocol: One-Stone-Two-Birds.

Authors:  Emily Rumschlag-Booms; Hongjie Zhang; D Doel Soejarto; Harry H S Fong; Lijun Rong
Journal:  J Antivir Antiretrovir       Date:  2011-01-07

Review 4.  Oseltamivir.

Authors:  A Bardsley-Elliot; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

5.  Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases.

Authors:  J N Varghese; P M Colman; A van Donkelaar; T J Blick; A Sahasrabudhe; J L McKimm-Breschkin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

6.  Non-carbohydrate inhibitors of the lectin DC-SIGN.

Authors:  M Jack Borrok; Laura L Kiessling
Journal:  J Am Chem Soc       Date:  2007-09-29       Impact factor: 15.419

7.  Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.

Authors:  Jennifer L McKimm-Breschkin; Janelle Williams; Susan Barrett; Kim Jachno; Mandy McDonald; Peter G Mohr; Takehiko Saito; Masato Tashiro
Journal:  J Antimicrob Chemother       Date:  2013-06-11       Impact factor: 5.790

8.  Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors.

Authors:  Christopher J Vavricka; Yue Liu; Hiromasa Kiyota; Nongluk Sriwilaijaroen; Jianxun Qi; Kosuke Tanaka; Yan Wu; Qing Li; Yan Li; Jinghua Yan; Yasuo Suzuki; George F Gao
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 9.  Using bacterial genomes and essential genes for the development of new antibiotics.

Authors:  Francisco R Fields; Shaun W Lee; Michael J McConnell
Journal:  Biochem Pharmacol       Date:  2016-12-08       Impact factor: 5.858

10.  Biexponential decomposition of a neuraminidase inhibitor prodrug (GS-4104) in aqueous solution.

Authors:  R Oliyai; L C Yuan; T C Dahl; S Swaminathan; K Y Wang; W A Lee
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.